Standardisation of measurements of neurodegenerative disease biomarkers

神经退行性疾病生物标志物测量的标准化

• 批准号: 10101600
• 金额: $ 19.43万
• 依托单位: LGC LTD
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10101600
• 关键词: Standardisation; measurements; neurodegenerative; disease; biomarkers

Neurodegenerative disorders (NDDs) affect over nine million Europeans and constitute a large economic burden to society. NDD biomarkers have transformed the research landscape by linking diseases to pathological processes and assisting drug development. NDD biomarkers improve the accuracy of diagnosis and prognosis with the use of non invasive tools. However, their implementation in clinical practice is hampered by a lack of standardisation. This project will build on previous EMPIR projects to standardise biomarker measurements, harmonise measurements across assay manufacturers, establish quality assessment programmes, develop and implement new biomarkers.

神经退行性疾病（NDD）影响了900多万欧洲人，并构成了社会的巨大经济负担。NDD生物标志物通过将疾病与病理过程联系起来并协助药物开发，改变了研究景观。NDD生物标志物通过使用非侵入性工具提高了诊断和预后的准确性。然而，它们在临床实践中的实施受到缺乏标准化的阻碍。该项目将建立在以前的EMPIR项目的基础上，以简化生物标志物测量，协调检测制造商之间的测量，建立质量评估计划，开发和实施新的生物标志物。